reason report
outlin gener posit trend opportun
gilead hiv product key find survey treat
us hiv patient growth grow singl digit pre-exposur prophylaxi
prep use could doubl gilead win increment market share
gsk defend increas hiv market posit
doublet today adjust market compani model
insight survey well recent disclosur gilead
gener entrant vs truvada patent outlook
us europ hiv medicin increas
gilead hiv estim period base longer
patent life key product descovi odefsey higher adopt
new brand includ biktarvi symtuza posit chang
slightli off-set decreas revenu estim
account recent announc gener truvada settlement
even though increas larg period
sustain beyond compani still like see
signific revenu eros post descovi loe reason
impact valuat increas overal valuat
new model valu hiv busi
share valu compani product hcv letairi
ranexa kite decreas pass year confid
valu gilead hiv busi increas remain cautiou
rest busi result compani new
capit alloc decis remain biggest variabl stock
signific uncertainti valuat healthi return
capit alloc stock could see signific upsid
choic fail exceed compani cost capit
stock outlook ultim valu could materi price
gilead hiv patient growth like low single-digit
gilead continu defend increas hiv market
share us launch biktarvi estim
number patient treat gilead brand gener medicin
surpass today expect patient
volum grow gener cliff gilead truvada
descovi declin margin gener dolutegravir
introduc
averag price-to-earnings large-cap revenu
multipl slower-growth medic co
sum part exist franchis
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm non-gaap ep ex stock option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
prep use hiv antivir doubl two year like
doubl forecast increas anoth next
year prep patient volum grown sequenti
last quarter use individu us
forecast growth moder continu forward reach
mid today prep volum truvada
goe gener septemb physician feedback descovi
prep posit recent survey gilead recent
announc posit phase trial result quickli file snda
new indic even though truvada face gener competit
limit year earlier forecast forecast gilead
retain volum descovi prep indic howev
descovi lose patent protect
model add updat patent term estim one
signific chang model updat latest patent
inform gilead given recent disclos settlement
teva mp model truvada declin start septemb
prior descovy-bas medicin declin start
prior also model small declin gilead
hiv portfolio introduct gener dolutegravir
ex-u hiv revenu estim remain global
hiv revenu gilead total ex-u hiv revenu remain
past year expect perform continu
model growth ex-u hiv revenu
expect ex-u hiv revenu remain less
gilead global hiv revenu ex-u market seem will trade
conveni perform newer combin lower
treatment cost wherea us seem commit provid
effect conveni well toler combin lack
growth ex-u hiv revenu support observ recent
hiv launch produc rel lower ex-u sale earlier
gener hiv medicin
limit chang total revenu estim gilead decreas
increas
period beyond estim
higher
total revenu estim line consensu forecast
new pro forma
ep estim lower essenti unchang
lower higher higher
pro forma ep estim also consensu
period result model chang
chang peer compani multipl increas price
rate gilead stock market perform price target gilead matur
gener biotech compani search next wave innov growth
compani leader hiv medicin busi increas alreadi domin market
share indic expect hiv product sale grow peak
expect signific eros taf/descovi franchis gilead
also built lead posit hepat medicin busi continu declin
headi peak two franchis believ worth compani
recent share price rest compani pipelin consist mainli late life cycl
product ranexa letairi commerci disappoint zydelig
yescarta kinas inhibitor filgotinib near term compani outlook
much depend result pivot trial nash medicin immedi
inhibitor firsocostat trial disappoint compani stock price could suffer
multipl compress expect compani revenu remain rang
next year earn hover rang level stock seem like
enjoy multipl line ex-growth matur biopharmaceut busi
upsid downsid risk come compani busi develop
capit alloc choic opportun
gilead total hiv revenu compani total revenu
like contribut compani profit gilead hiv revenu continu grow
non-hiv revenu declin remain flattish next sever year mean
hiv contribut even larger share total revenu today introduc new hiv
market model increasingli import busi segment previous forecast
sale gilead entir hiv franchis base gilead total us prescript growth trend
sourc iqvia alloc differ brand estim volum
product base best judgment individu product trend replac model
patient-bas model sourc gilead disclos number hiv-infect patient
hiv therapi sourc iqvia number patient pre-
exposur prophylaxi prep forecast separ growth rate treat hiv-infect
prep patient alloc patient individu gilead hiv medicin whether
brand gener revenu gilead gener base im compani provid
data overal hiv market model captur multipl signific chang compar prior
latest hiv-infect prep patient growth trend well product share shift
trend
latest patent expir assumpt gilead gsk hiv medicin
materi chang taf-bas product exclus compar
prior estim truvada go gener compar
faster switch biktarvi expens stribild genvoya odefsey
higher penetr symtuza later line hiv treatment
explicit model prep market includ continu substanti growth
partial switch prep patient truvada descovi
estim market growth product share includ switch rate base
market trend well result recent medacorp hiv survey
hiv survey pt market growth continu prep could doubl
hiv survey pt playoff time best offens gsk defens solid
model averag sequenti quarterli growth gilead hiv treat patient volum
us balanc lower report averag sequenti growth
moder growth trajectori
translat total hiv treatment volum growth
thereaft total expect hiv patient treat
brand gener version gilead medicin peak prep set model
substanti higher growth trend annual prep volum growth declin
later year gilead disclos quarterli prep
growth year estim prep patient brand gener gilead
medicin reach individu
enter estim gilead genvoya highest hiv patient share
newli launch biktarvi reach first year within prep truvada
patient therapi time expect biktarvi grow hiv patient
share peak genvoya fall mid-singl digit share also expect symtuza grow
materi hiv patient share peak prep expect descovi approv
launch captur prep patient share compani
product reach patent expir shift volum gener product line
time grow combin us hiv prep patient volum exhibit
exhibit current estim us hiv prep patient share gilead portfolio
forecast gilead global hiv revenu grow estim
prior estim driven primarili reduct forecast atripla genvoya
odefsey also trim global hiv estim
captur author gener truvada launch one year earlier prior
expect howev begin increas expect gilead
hiv revenu primarili driven longer patent exclus robust adopt symtuza
descovi global hiv estim increas
estim also increas
estim unchang exhibit
exhibit chang annual svb leerink total hiv estim
updat estim line consensu consensu
howev estim declin consensu
consensu exhibit estim construct
near- mid-term biktarvi descovi growth pessimist long-term
chang model expect gilead hiv busi remain import
driver compani financi perform next decad estim hiv
franchis gener gilead total revenu grow peak
gilead total revenu even toward end decad sever import
patent cliff gilead hiv medicin hiv revenu still gilead total revenu
exhibit proport hiv revenu total product sale
us hiv patent cliff occur gsk dolutegravir loe
signific chang hiv forecast gener caus loss exclus
loe gilead product rather introduct competit product subsequ
loss market share mani gilead commonli use hiv medicin multi-drug
therapi combin brand one pill combin pill compos one
drug compon alreadi gone gener gener entri block
final loe occur last compon result gilead hiv tend occur
tranch two upcom tranch set occur us
purpos forecast assum exclus combin last loss
exclus last compon combin combin product hold
price avail substitut gener version combin pill
us loe period associ patent expir emtricitabin tenofovir
disoproxil fumar tdf two medicin combin truvada previous
expect go gener septemb gilead disclos latest prior
settlement teva mp allow gener entri septemb truvada also
combin singl medicin compris atripla complera stribild atripla
also expect go gener complera stribild contain extra compon
provid patent protect single-tablet regimen respect
us loe period tie patent expir vemlidi tenofovir alafenamid taf taf
second compon descovi along emtricitabin alreadi gener
two medicin also combin odefsey jnj rilpivirin also goe
gener allow gener odefsey launch taf backbon also use
genvoya biktarvi booster tybost keep genvoya protect
integras inhibitor bictegravir keep biktarvi protect exhibit
period patent expir result materi reduct number estim us
hiv/prep patient gilead brand medicin model assum quickli
switch gener version quarter largest impact prep
assum biktarvi symtuza genvoya captur vast major hiv patient share
import occur limit number patient lost gilead brand
medicin gener earlier medicin howev gilead patent protect prep
descovi even though model descovi extend signific portion
gilead prep patient share model compani lose revenu
prep patient begin
overal expect number us hiv/prep patient brand gilead medicin grow
averag fall
due exhibit
druggenericu loeeu loevireadtenofovir disoproxil disoproxil disoproxil disoproxil penid descovyemtricitabine/tenofovir penid odefseyrilpivirine/emtricitabine/tenofovir disoproxil darunavir/cobicistat/emtricitabine/tenofovir compon expir us loe gilead scienc inc
exhibit actual estim us hiv/prep patient gilead brand medic
ex-u hiv product launch moder
gilead total ex-u hiv revenu remain past year
grown manner hiv revenu us lack growth ex-u hiv market
due gilead fail win regulatori approv next-gener hiv medicin
market due system pressur pressur ex-u market prevent total
revenu growth price cut certain countri earlier entri gener version certain
gilead hiv medicin slower launch newer gilead hiv medicin
sinc us hiv revenu grown ex-u hiv revenu stagnat gilead total hiv
revenu becom increasingli reliant perform us market gilead
ex-u hiv revenu global hiv revenu ex-u revenu proport almost
halv global hiv revenu look forward forecast trend
downward ex-u revenu mix continu forecast ex-u
percentag global hiv revenu respect howev expect
biktarvi begin gain traction ex-u market off-set price
volum eros caus gener older combin forecast ex-u hiv revenu
grow year forecast ex-u hiv revenu
global hiv revenu exhibit
exhibit actual estim total gilead hiv revenu geograph mix
state earlier hiv ex-u sale pressur partial due slower launch gilead
newest hiv medicin compar launch trajectori earlier combin product older
hiv drug complera atripla launch quickli ex us sale grew
us revenu fast ex-u sale ramp also occur gsk earlier gener
hiv medicin triumeq tivicay grew us sale year year
howev recent ex-u launch gilead hiv medicin includ descovi
odefsey genvoya grown us sale year drug
appear trend rang preced product exhibit
exhibit ex-u us hiv product revenu ratio
declin rel success brand hiv drug launch market outsid us
evid scatter plot year ex-u us sale ratio year drug launch
trend downward newer launch exhibit achiev lower year
sale predecessor
exhibit declin trend year ex-u us sale ratio
gilead price increas
base chang hiv forecast gilead total revenu estim gilead
decreas decreas howev gilead total
revenu estim increas also increas
total revenu estim line consensu forecast
decreas oper expens
increas expens account higher sale
overal continu expect gilead report flat slightli declin oper margin
increas spend sale off-set lower cost good chang
product mix toward wholli own combin result estim oper margin
fluctuat given year new pro forma ep estim lower
unchang lower higher higher
pro forma ep estim also consensu period
result chang chang peer compani multipl
increas price continu rate gilead market perform primarili
substanti uncertainti compani pipelin capit alloc
prioriti return given compani strong cash posit total net cash
futur cash flow abil leverag biggest variabl
compani outlook stock price like whether gener
higher return invest capit gilead achiev lower higher return
current net cash next decad post-dividend free cash flow compar cost
ex-u us sale ratio count start first year ou sale year drug launch gilead scienc inc
capit calcul valu stock could much lower
higher updat price target
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap medic product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough consensu
forward earn multipl slow-growth medic product stock celg
appli ep estim gilead give price
altern appli slow-grow large-cap biopharma product
rhhbi nv revenu multipl revenu estim deriv
impli valu impli one year price target use sum part
valuat exist franchis get price consist primarili
compani hiv franchis hcv product lastli dcf use forecast free
cash flow appli growth rate termin cash flow forecast
discount valu back present wacc give present valu
averag four approach price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product risk
busi also includ emerg aggress price discount rebat
valu eros current forecast gilead also risk failur
compani princip pipelin asset firsocostat nash filgotinib ra ibd opportun
better perform valu expect includ delay limit
develop profil adopt competit hiv product success develop
underappreci element compani portfolio fxr agonist follow-
car-t indic stronger-than-expect convers current hiv patient gilead
svb leerink llc research compani file zack factset consensu
svb leerink llc research compani file zack factset consensu
brand
type event
event trial detail
date known
up/down
expect
svb leerink llc research compani file
phase result
phase result registr
phase ii result registr
phase result
file fda regulatori approv mcl
phase ii testicular safeti filgotinib result
manta gate nda
million
symtuza darunavir/c/f-taf royalti
symtuza darunavir/c/f-taf royalti
svb leerink llc research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
svb leerink llc research compani file
analysi stock price svb leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep celg
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
svb leerink revenu estim gilead
comp ex growth larg cap revenu multipl
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
svb leerink llc partner research compani file factset
